Monday, August 15, 2022
HomeWeekly RoundupAspen launches once-a-day HIV drug in SA

Aspen launches once-a-day HIV drug in SA

South African drug-maker Aspen Pharmacare has launched a triple-combination tablet for the treatment of HIV in the country where the virus is most prevalent, reports Reuters Health. The company’s new Emdolten drug is a once-a-day tablet in the form of dolutegravir, an antiretroviral medication that counters the drug resistance that often develops with older HIV treatments, Aspen said. The drug also contains lamivudine and tenofovir disoproxil fumarate alongside dolutegravir.

The report says in May the South African Health Products Regulatory Authority and the European Medicines Agency issued a warning advising doctors not to prescribe dolutegravir to women seeking to become pregnant. This followed preliminary data from a study in Botswana, which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

The drug is found in the branded medicines Tivicay and Triumeq, which are sold by GlaxoSmithKline’s majority-owned ViiV Healthcare unit.

Aspen, which pioneered the development and manufacture of generic antiretrovirals (ARV) in South Africa, said in the report that using dolutegravir was safe for men, women who are not of child bearing age and child-bearing women using contraceptives, adding that these groups represent more than 70% of HIV patients. “The fact that it (Emdolten) has been registered means that SAHPRA is comfortable that it is safe to take to the public,” Aspen strategic trade executive Stavros Nicolaou said, referring to South African Health Products Regulatory Authority.

The report says the company launched Aspen Stavudine – its first generic ARV drug in August 2003 – at a time when the country was grappling with a high rate of HIV infection.

South Africa has 19% of the global number of people living with HIV, 15% of new infections and 11% of Aids-related deaths, the UNAIDS agency says on its website.

There is no vaccine to prevent HIV/Aids. Current treatments only helping patients to manage the disease, but the fast-mutating virus has proved a challenge to the medical community because it often develops resistance to existing medicines.

[link url=""]Reuters Health report[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required